Opinion · 25 Jun 2026
Conference abstractPublished 5 Aug 2013
The challenge of genetic diversity in clinical trials: Is precision medicine up to the challenge?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Precision Medicine is a drug development paradigm that has evolved within oncology where cancer-causing genetic mutations have been known or suspected for some time, and where the toxicity and poor efficacy of non-specific chemotherapeutics promoted the search for targeted, less toxic therapies against these mutations. While programs like trastuzumab for HER-2 over-expression in breast cancer, crizotinib for ALK fusion proteins in NSCLC, and vemurafinib for BRAF V600E mutations in melanoma are shining success stories for Precision Medicine, there are surprisingly few others. It has become very apparent that despite the application of Precision Medicine the response rates in oncology clinical trials have not approached 100% or even come close. The leading hypothesis is that intra-tumor genetic diversity of distinct subpopulations of cells is the key driver for resistance and the disappointing results with targeted therapies. The recent tumor sequencing work to date suggests that how, when and where tumor samples are collected and analyzed need to be thoughtfully planned and implemented in clinical trials in order to maximize the utility of this genetic diversity information for patient selection criteria or for post-hoc subgroup analysis. While oncology has been the original playground for Precision Medicine, examples of other diseases/therapeutic areas where these patient selection criteria are likely to be very beneficial in improving the successes of clinical trials will also be briefly discussed. The future of Precision Medicine is promising, and if implemented carefully and consistently should improve clinical trial success rates and deliver more effective treatments for physicians and patients.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Translational Medicine.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Paul A. Frohna”
